Moderna (MRNA) Competitors $25.27 -0.12 (-0.47%) As of 10:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRNA vs. CRSP, CVAC, HOOD, NVAX, OCGN, TSLA, JNJ, MRK, PFE, and INSMShould you be buying Moderna stock or one of its competitors? The main competitors of Moderna include CRISPR Therapeutics (CRSP), CureVac (CVAC), Robinhood Markets (HOOD), Novavax (NVAX), Ocugen (OCGN), Tesla (TSLA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), and Insmed (INSM). Moderna vs. Its Competitors CRISPR Therapeutics CureVac Robinhood Markets Novavax Ocugen Tesla Johnson & Johnson Merck & Co., Inc. Pfizer Insmed Moderna (NASDAQ:MRNA) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation. Do analysts prefer MRNA or CRSP? Moderna presently has a consensus target price of $42.88, suggesting a potential upside of 69.54%. CRISPR Therapeutics has a consensus target price of $71.60, suggesting a potential upside of 27.88%. Given Moderna's higher possible upside, equities research analysts plainly believe Moderna is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 4 Sell rating(s) 16 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04CRISPR Therapeutics 1 Sell rating(s) 7 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.47 Which has better valuation and earnings, MRNA or CRSP? CRISPR Therapeutics has lower revenue, but higher earnings than Moderna. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$3.24B3.04-$3.56B-$7.53-3.36CRISPR Therapeutics$37.31M136.49-$366.25M-$5.43-10.31 Is MRNA or CRSP more profitable? Moderna has a net margin of -94.31% compared to CRISPR Therapeutics' net margin of -1,229.43%. CRISPR Therapeutics' return on equity of -20.05% beat Moderna's return on equity.Company Net Margins Return on Equity Return on Assets Moderna-94.31% -25.96% -20.09% CRISPR Therapeutics -1,229.43%-20.05%-17.09% Which has more volatility and risk, MRNA or CRSP? Moderna has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Do institutionals & insiders hold more shares of MRNA or CRSP? 75.3% of Moderna shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 11.0% of Moderna shares are owned by insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media refer more to MRNA or CRSP? In the previous week, Moderna had 7 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 17 mentions for Moderna and 10 mentions for CRISPR Therapeutics. Moderna's average media sentiment score of 1.03 beat CRISPR Therapeutics' score of 0.77 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 9 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive CRISPR Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryModerna beats CRISPR Therapeutics on 10 of the 17 factors compared between the two stocks. Get Moderna News Delivered to You Automatically Sign up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRNA vs. The Competition Export to ExcelMetricModernaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.80B$3.18B$5.82B$10.13BDividend YieldN/A2.32%5.69%4.62%P/E Ratio-3.3521.5074.8626.13Price / Sales3.04297.34467.6691.41Price / CashN/A45.3337.0859.91Price / Book0.899.6812.096.33Net Income-$3.56B-$53.32M$3.29B$270.76M7 Day Performance0.61%0.87%1.42%3.50%1 Month Performance-1.43%9.65%7.70%6.83%1 Year Performance-63.70%13.23%62.04%28.21% Moderna Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRNAModerna4.5215 of 5 stars$25.27-0.5%$42.88+69.7%-68.1%$9.82B$3.24B-3.355,800Positive NewsCRSPCRISPR Therapeutics3.3247 of 5 stars$54.56-0.5%$71.60+31.2%+23.0%$4.97B$37.31M-10.06460CVACCureVac3.9426 of 5 stars$5.37-0.5%$6.83+27.4%+77.9%$1.20B$579.18M5.59880Short Interest ↑HOODRobinhood Markets3.9249 of 5 stars$115.41+14.0%$100.31-13.1%+470.5%$102.57B$3.57B58.592,300Trending NewsAnalyst ForecastInsider TradeNVAXNovavax4.5049 of 5 stars$7.69-2.7%$14.29+85.9%-32.6%$1.24B$682.16M3.361,990Positive NewsOCGNOcugen1.931 of 5 stars$1.03-0.5%$6.00+485.4%-13.0%$296.68M$4.05M-5.0780Positive NewsTSLATesla4.2131 of 5 stars$346.82-1.1%$303.00-12.6%+61.7%$1.12T$97.69B200.11125,665Trending NewsInsider TradeJNJJohnson & Johnson4.6585 of 5 stars$178.52+0.0%$176.29-1.3%+8.2%$429.91B$88.82B19.09138,100Positive NewsAnalyst RevisionMRKMerck & Co., Inc.4.9965 of 5 stars$83.85-1.0%$107.44+28.1%-25.8%$209.36B$64.17B12.9275,000Positive NewsPFEPfizer4.9749 of 5 stars$24.56-1.3%$28.12+14.5%-16.2%$139.63B$63.63B13.0681,000Positive NewsINSMInsmed3.3624 of 5 stars$146.05+0.7%$139.86-4.2%+100.4%$30.77B$363.71M-25.491,271Positive News Related Companies and Tools Related Companies CRISPR Therapeutics Alternatives CureVac Alternatives Robinhood Markets Alternatives Novavax Alternatives Ocugen Alternatives Tesla Alternatives Johnson & Johnson Alternatives Merck & Co., Inc. Alternatives Pfizer Alternatives Insmed Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRNA) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersNVDA: The cracks are beginning to showThe media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. I...InvestorPlace | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moderna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moderna With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
